Praziquantel

Summary

Praziquantel (CHEMBL976) is an approved small molecule (ATC P02BA01); indicated across 7 conditions including schistosomiasis and helminthiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P02BA01
• Indications: 7 conditions
• Clinical trials: 37
• Chemistry: 312.4 Da · C19H24N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL976
Name	Praziquantel
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4891
ATC	P02BA01
Molecular formula	C19H24N2O2
Molecular weight	312.4
InChIKey	FSVJFNAIGNNGKK-UHFFFAOYSA-N

SMILES: C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2

IUPAC name: 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one

Also known as: Biltricide, Cesol, Cisticid, Cysticide, Cestocur, EMBAY 8440, EMBAY-8440, NSC-757285, Prazicuantel, Praziquantel, Praziquantel component of broadline, Praziquantel component of profender

Patent coverage: 4,086 distinct patent families (13,070 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 12,899 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Survival motor neuron protein, Prelamin-A/C, RecQ-like DNA helicase BLM, Kappa-type opioid receptor, Muscarinic acetylcholine receptor M1, Cytochrome P450 3A4, Aldehyde dehydrogenase 1A1, Mitogen-activated protein kinase 1, Cellular tumor antigen p53, Neuropeptide S receptor, Bile salt export pump.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 18 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
BLM	8.49	Potency	3.2	nM	CHEMBL_ACT_4746015
BLM	8.49	Potency	3.2	nM	CHEMBL_ACT_4929720
TP53	6.9	Potency	125.9	nM	CHEMBL_ACT_4874103
SMN1	5.85	Potency	1412	nM	CHEMBL_ACT_3889455
NPSR1	5.2	Potency	6310	nM	CHEMBL_ACT_4940733

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
schistosomiasis	4	MONDO:0015254	EFO:1001475
helminthiasis	4	MONDO:0004664	EFO:1001342
opisthorchiasis	4	MONDO:0005884	EFO:0007404

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
cysticercosis	3	MONDO:0015484	EFO:0007231
urinary schistosomiasis	3	MONDO:0006001	EFO:0007530
Schistosoma mansoni infectious disease	2	MONDO:0044345	MONDO:0008412

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 37.

Phase distribution

Phase	Trials
Not specified	15
PHASE3	6
PHASE4	5
PHASE1	5
PHASE2/PHASE3	3
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06376396	PHASE4	NOT_YET_RECRUITING	Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
NCT07074444	PHASE4	RECRUITING	Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel
NCT00403611	PHASE4	COMPLETED	Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil
NCT02734186	PHASE4	WITHDRAWN	Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis
NCT02878564	PHASE4	COMPLETED	Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology
NCT00441285	PHASE2/PHASE3	COMPLETED	Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
NCT00510159	PHASE2/PHASE3	COMPLETED	Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis
NCT01054651	PHASE3	COMPLETED	A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni
NCT01558336	PHASE3	COMPLETED	Schistosoma Haematobium Infections and Praziquantel
NCT01722539	PHASE3	COMPLETED	Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren
NCT02947581	PHASE3	TERMINATED	Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
NCT03779347	PHASE3	UNKNOWN	Schistosomiasis Diagnosis Using a CAA Antigen Test
NCT03893097	PHASE3	COMPLETED	Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children
NCT04679831	PHASE2/PHASE3	COMPLETED	Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni
NCT00486863	PHASE2	COMPLETED	S. Japonicum and Pregnancy Outcomes
NCT01901484	PHASE2	COMPLETED	Schistosoma Mansoni Morbidity in Children Aged 1-5 Years
NCT03640377	PHASE2	COMPLETED	Praziquantel in Children Under Age 4
NCT01288872	PHASE1	COMPLETED	Praziquantel-Pharmacokinetic Study
NCT02271984	PHASE1	COMPLETED	Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers
NCT02325713	PHASE1	COMPLETED	Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers
NCT03437447	PHASE1	COMPLETED	Praziquantel Bioequivalence Study
NCT04314037	PHASE1	COMPLETED	Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide
NCT00215267	Not specified	COMPLETED	The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda
NCT00231322	Not specified	COMPLETED	Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique
NCT00347113	Not specified	COMPLETED	Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania
NCT00507221	Not specified	COMPLETED	Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression
NCT00817713	Not specified	TERMINATED	Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?
NCT01050374	Not specified	COMPLETED	Safety and Efficacy of Drug Combinations Against Schistosomiasis
NCT01050517	Not specified	COMPLETED	Safety and Efficacy of Drug Combinations Against Triple Infections
NCT01154907	Not specified	UNKNOWN	Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa
NCT01260012	Not specified	UNKNOWN	Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis
NCT01541631	Not specified	UNKNOWN	A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
NCT02144389	Not specified	COMPLETED	Arachidonic Acid Treatment Against Schistosomiasis Infection in Children
NCT02162875	Not specified	COMPLETED	Schistosoma Mansoni in Mwanza Region, Tanzania
NCT02612896	Not specified	COMPLETED	Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?
NCT04635553	Not specified	UNKNOWN	Monitoring Schistosome Hybrids Under Under Praziquantel Pressure
NCT05354258	Not specified	UNKNOWN	Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 6 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).